<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2039">
  <stage>Registered</stage>
  <submitdate>7/07/2008</submitdate>
  <approvaldate>7/07/2008</approvaldate>
  <nctid>NCT00712348</nctid>
  <trial_identification>
    <studytitle>Switchover Trial From Imiglucerase to Plant Cell Expressed Recombinant Human Glucocerebrosidase</studytitle>
    <scientifictitle>A Phase 3 Multicenter, Open-label, Switchover Trial to Assess the Safety and Efficacy of Plant Cell Expressed Recombinant Human Glucocerebrosidase in Patients With Gaucher Disease Treated With Imiglucerase</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>PB-06-002</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Gaucher Disease</healthcondition>
    <conditioncode>
      <conditioncode1>Human Genetics and Inherited Disorders</conditioncode1>
      <conditioncode2>Other human genetics and inherited disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Taliglucerase alfa

Experimental: Taliglucerase alfa - Open label taliglucerase alfa treatment


Treatment: drugs: Taliglucerase alfa
Intravenous infusion every 2 weeks

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Hemoglobin</outcome>
      <timepoint>Every 3 months from Baseline to Month 9</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Males and females, 2 years or older

          -  Confirmed diagnosis of Gaucher disease by the enzymatic activity assay

          -  Stable Gaucher disease

          -  Treatment with imiglucerase (Cerezyme速) for at least 2 years and on a stable
             maintenance regimen (dose and regimen unchanged, except for situation of drug
             shortage) for at least the last six months

          -  Able to provide written informed consent</inclusivecriteria>
    <inclusiveminage>2</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Currently taking another experimental drug for any condition

          -  History of allergy to carrots

          -  History of allergy to beta lactam antibiotics

          -  Previous infusion reaction suspected to be allergic in nature to Cerezyme速 or
             Ceredase速 or receiving premedication to prevent infusion reactions

          -  Presence of HIV and/or HBsAg and/or hepatitis C infection

          -  Presence of unresolved anemia due to iron, folic acid or vitamin B12 deficiency

          -  Presence of any significant comorbidity that could confound the interpretation of the
             clinical response to taliglucerase alfa

          -  Presence of any medical, emotional, behavioral or psychological condition that in the
             judgment of the Investigator would interfere with the patient's compliance with the
             requirements of the study</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/12/2008</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>31</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/05/2013</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Bone Marrow Transplant Service, The Royal Melbourne Hospital - Parkville</hospital>
    <postcode> - Parkville</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Haifa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Jerusalem</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Zaragoza</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Cambridge</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Protalix</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a multi-center, open-label, switchover trial to assess the safety of taliglucerase
      alfa in 30 patients with Gaucher disease who are currently being treated with imiglucerase
      (Cerezyme速) enzyme replacement therapy.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00712348</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Ari Zimran, MD</name>
      <address>Shaare Zedek Medical Center, Jerusalem</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>